AAAAAA
Results:
1-20
|
Results: 20
Authors:
Judson, I
Radford, JA
Harris, M
Blay, JY
van Hoesel, Q
le Cesne, A
van Oosterom, AT
Clemons, MJ
Kamby, C
Hermans, C
Whittaker, J
di Paola, ED
Verweij, J
Nielsen, S
Citation: I. Judson et al., Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL (R)/CAELYX (R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group, EUR J CANC, 37(7), 2001, pp. 870-877
Authors:
Wagenaar, HC
Pecorelli, S
Mangioni, C
van der Burg, MEL
Rotmensz, N
Anastasopoulou, A
Zola, P
Veenhof, CHN
Lacave, AJ
Neijt, JP
van Oosterom, AT
Einhorn, N
Vermorken, JB
Citation: Hc. Wagenaar et al., Phase II study of mitomycin-C and cisplatin in disseminated, squamous cellcarcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study, EUR J CANC, 37(13), 2001, pp. 1624-1628
Authors:
Sparidans, RW
Rosing, H
Hillebrand, MJX
Lopez-Lazaro, L
Jimeno, JM
Manzanares, I
van Kesteren, C
Cvitkovic, E
van Oosterom, AT
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man, ANTI-CANC D, 12(8), 2001, pp. 653-666
Authors:
Aerts, J
Wynendaele, W
Paridaens, R
Christiaens, MR
van den Bogaert, W
van Oosterom, AT
Vandekerckhove, F
Citation: J. Aerts et al., A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood, ANN ONCOL, 12(1), 2001, pp. 39-46
Authors:
Sternberg, CN
de Mulder, PHM
Schornagel, JH
Theodore, C
Fossa, SD
van Oosterom, AT
Witjes, F
Spina, M
van Groeningen, CJ
de Balincourt, C
Collette, L
Citation: Cn. Sternberg et al., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancerprotocol no. 30924, J CL ONCOL, 19(10), 2001, pp. 2638-2646
Authors:
van Oosterom, AT
Judson, I
Verweij, J
Stroobants, S
di Paola, ED
Dimitrijevic, S
Martens, M
Webb, A
Sciot, R
Van Glabbeke, M
Silberman, S
Nielsen, OS
Citation: At. Van Oosterom et al., Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study, LANCET, 358(9291), 2001, pp. 1421-1423
Authors:
Dumez, H
Highley, M
Guetens, G
De Boeck, G
Hanauske, A
van Oosterom, AT
Maes, RAA
de Bruijn, EA
Harper, P
Citation: H. Dumez et al., Erythrocytes and the transfer of anticancer drugs and metabolites: A possible relationship with therapeutic outcome, SEMIN ONCOL, 28(2), 2001, pp. 24-28
Authors:
Therasse, P
Arbuck, SG
Eisenhauer, EA
Wanders, J
Kaplan, RS
Rubinstein, L
Verweij, J
Van Glabbeke, M
van Oosterom, AT
Christian, MC
Gwyther, SG
Citation: P. Therasse et al., New guidelines to evaluate the response to treatment in solid Tumors, J NAT CANC, 92(3), 2000, pp. 205-216
Authors:
Zhang, ZD
Guetens, G
De Boeck, G
Van Cauwenberghe, K
Maes, RAA
Ardiet, C
van Oosterom, AT
Highley, M
de Bruijn, EA
Tjaden, UR
Citation: Zd. Zhang et al., Simultaneous determination of the peptide-mitomycin KW-2149 and its metabolites in plasma by high-performance liquid chromatography, J CHROMAT B, 739(2), 2000, pp. 281-289
Authors:
Guetens, G
Van Cauwenberghe, K
De Boeck, G
Maes, R
Tjaden, UR
van der Greef, J
Highley, M
van Oosterom, AT
de Bruijn, EA
Citation: G. Guetens et al., Nanotechnology in bio/clinical analysis, J CHROMAT B, 739(1), 2000, pp. 139-150
Authors:
Paridaens, R
Uges, DRA
Barbet, N
Choi, L
Seeghers, M
van der Graaf, WTA
Groen, HJM
Dumez, H
Van Buuren, I
Muskiet, F
Capdeville, R
van Oosterom, AT
de Vries, EGE
Citation: R. Paridaens et al., A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours, BR J CANC, 83(5), 2000, pp. 594-601
Authors:
Fokkema, E
Verweij, J
van Oosterom, AT
Uges, DRA
Spinelli, R
Valota, O
de Vries, EGE
Green, HJM
Citation: E. Fokkema et al., A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study, BR J CANC, 82(4), 2000, pp. 767-771
Authors:
Pawinski, A
Crowther, D
Keizer, HJ
Voute, PA
Somers, R
van Glabbeke, M
Lentz, MA
van Oosterom, AT
Citation: A. Pawinski et al., The EORTC phase II study of iproplatin in advanced osteogenic sarcoma, EUR J CANC, 35(1), 1999, pp. 163-164
Authors:
Sandler, A
van Oosterom, AT
Citation: A. Sandler et At. Van Oosterom, Irinotecan in cancers of the lung and cervix, ANTI-CANC D, 10, 1999, pp. S13-S17
Authors:
Wynendaele, W
Derua, R
Hoylaerts, MF
Pawinski, A
Waelkens, E
de Bruijn, EA
Paridaens, R
Merlevede, W
van Oosterom, AT
Citation: W. Wynendaele et al., Vascular endothelial growth factor measured in platelet poor plasma allowsoptimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?, ANN ONCOL, 10(8), 1999, pp. 965-971
Authors:
Van Glabbeke, M
van Oosterom, AT
Oosterhuis, JW
Mouridsen, H
Crowther, D
Somers, R
Verweij, J
Santoro, A
Buesa, J
Tursz, T
Citation: M. Van Glabbeke et al., Prognostic factors for the outcome of chemotherapy in advanced soft tissuesarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatmentof Cancer Soft Tissue and Bone Sarcoma Group Study, J CL ONCOL, 17(1), 1999, pp. 150-157
Authors:
Highley, MS
van Oosterom, AT
Maes, RA
De Bruijn, EA
Citation: Ms. Highley et al., Intravesical drug delivery - Pharmacokinetic and clinical considerations, CLIN PHARMA, 37(1), 1999, pp. 59-73
Authors:
Pawinski, A
Tumolo, S
Hoesel, G
Cervantes, A
van Oosterom, AT
Boes, GH
Pecorelli, S
Citation: A. Pawinski et al., Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group, EUR J OB GY, 86(2), 1999, pp. 179-183
Authors:
van Oosterom, AT
Citation: At. Van Oosterom, Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: Results to date and an overview of ongoing studies, SEMIN ONCOL, 26(3), 1999, pp. 8-11
Authors:
Wynendaele, W
van Oosterom, AT
Pawinski, A
de Bruijn, EA
Maes, RA
Citation: W. Wynendaele et al., Angiogenesis: possibilities for therapeutic interventions, PHARM WORLD, 20(6), 1998, pp. 225-235
Risultati:
1-20
|